No Data
Insider Spends US$99k Buying More Shares In Prelude Therapeutics
Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating
Prelude Therapeutics (PRLD) Gets a Sell From Morgan Stanley
Prelude Therapeutics Reports Promising Interim Data for PRT2527 in Relapsed/Refractory Lymphoid Malignancies, Plans Partnership for Future Development
Express News | Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies
No Data
